CMS predicts fewer Xigris patients
Executive Summary
Centers for Medicare and Medicaid Services is revising downward estimates for add-on payments for Lilly's Xigris (drotrecogin alfa). Agency estimates 14,000 Medicare patients will be administered therapy in fiscal 2004 compared to 22,000-patient estimate for FY 2003. CMS' original 2003 payment estimate assumed 50,000 Medicare patients (1"The Pink Sheet" Aug. 5, 2002, p. 18) Xigris sales have not matched Lilly's expectations (2"The Pink Sheet" Nov. 18, 2002, p. 22)...
You may also be interested in...
Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages
Lilly is planning to publish a series of peer-reviewed Xigris journal articles as part of a continued effort to build market acceptance of the sepsis agent
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
The Centers for Medicare & Medicaid Services is estimating that the Medicare market for Lilly's Xigris will be $340 mil. in fiscal year 2003
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.